Study of MK0663 in Patients With Chronic Low Back Pain (0663-806)(COMPLETED)

A Double-Blind, Parallel-group, 4-Week Trial to Assess the Efficacy and Safety of Etoricoxib 60 mg and Diclofenac 150 mg in Patients With Chronic Low Back Pain

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00090181

Enrollment

401

Registered

2004-08-27

Start date

2004-06-30

Completion date

2005-03-31

Last updated

2022-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Low Back Pain

Keywords

Arcoxia

Brief summary

The purpose of this study is to evaluate the efficacy of MK0663 for the treatment of chronic low back pain and to investigate the overall safety and tolerability over four weeks of treatment.

Interventions

DRUGMK0663, etoricoxib / Duration of Treatment: 4 weeks

DRUGComparator: diclofenac / Duration of Treatment: 4 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male and female patients 18 years of age or older, who have Chronic Low Back Pain after the discontinuation of their previous medication for their condition. * Patients should have at least 3 months of Low Back Pain.

Design outcomes

Primary

Measure	Time frame
Lower back pain intensity	—
Safety and tolerability	—

Secondary

Measure	Time frame
Disability questionnaire	—
Patient global assessment of response to therapy	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026